| 摘要 |
The present invention concerns a compound of general formula (I) wherein: R<SUB>1</SUB>, R<SUB>2</SUB> and R<SUB>3</SUB> mean, independently from the others, an hydrogen atom or an optionally substituted lower alkyl, a (C1-C7) acyI group or a benzyl, R<SUB>4</SUB> is an optionally substituted and/or interrupted hydrocarbon linker, X and Y are selected independently from each other from the group consisting of -NH-, -NR'-, -CO-, -NH(CO)-, -NH(CO)NH-, -NR'(C0)-, -0(CO)NH-, -O(CO)NR'-, -(CO)NH-, -(CO)NR'-, -NH(CO)(R' ')NH(CO)-, -(CO)NH(R")(CO)NH-, - O-? -(CO)O-, -NH(CO)O-, -SC(O)NH-, -NHSO2-, -NR'SO2- -O(CO)-, -S-S-, - OC(O)NHR^C(O)NH-, -NHC(O)R"-, -OC(O)R"-, -OC(O)NH-R"- and -NHC(O)NH- R"-, and preferably are different one from the other, with R' being an optionally substituted lower alkyl group, and R" being a (C<SUB>1</SUB>-C<SUB>3</SUB>)alkylene, Z moiety represents an anti-neoplasic agent, n means 0, 1 or 2, and the pharmaceutically acceptable salts thereof. It relates also to the use of such compounds as anti cancer agents. |
